Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $13.58 a share, with a consensus analyst price target of $23.00 and a 52-week trading range of $7.67 to $18.00.
Endocyte Inc. (NASDAQ: ECYT) will present data in regards to its PSMA-617 at the Society of Nuclear Medicine and Molecular Imaging annual meeting on June 23 to 26. PSMA-617 is a radioligand therapy for the targeted treatment of prostate cancer. Shares of Endocyte were last seen at $13.79 on Friday, with a consensus price target of $17.67 and a 52-week range of $1.17 to $15.45.
Achaogen Inc. (NASDAQ: AKAO) has a Prescription Drug User Fee Act (PDUFA) date scheduled for June 25 for its lead product, plazomicin, which is being developed to treat serious bacterial infections. Achaogen shares traded at $12.42, with a consensus price target of $18.20 and a 52-week range of $9.83 to $25.22.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is readying for its commercial launch of Palynziq (pegvaliase) in the United States, for the treatment of phenylketonuria. Shares of BioMarin were trading at $99.03, with a consensus analyst target of $114.14 and a 52-week range of $75.81 to $99.76.
24/7 Wall St.Global Blood Therapeutics Inc. (NASDAQ: GBT) is expected to announce Part A (dose finding for Part B) of its Phase 3 HOPE trial for people with sickle cell disease later this month. Shares of GBT were last seen at $42.05 on Friday, with a consensus price target of $72.46 and a 52-week range of $24.02 to $68.05.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.78, with a consensus analyst target of $80.17 and a 52-week range of $22.25 to $76.29.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
